American Urological Association
Education & Research, Inc.

AUA VIRTUAL EXPERIENCE

IL-10 AND CXCL10 URINE QUANTIFICATION AS USEFUL BIOMARKERS TO PREDICT BCG RESPONSE IN BLADDER CANCER PATIENTS

MP01-16
Abs 4386

Félix Guerrero-Ramos MD PhD *et al.*
Dept. of Urology, Hospital Universitario 12 de Octubre (Madrid, Spain)
Molecular Oncology Unit, CIEMAT (Madrid, Spain)
@DrFelixGuerrero

BACKGROUND

Currently there is no way to predict response to BCG in high risk NMIBC

AIM

1. Can urine IL-10 & CXCL10 measured before the TURBT predict response to BCG?
2. Do their urine levels correlate with the presence of M2 cells in tumor tissue?

MATERIALS AND METHODS

1. Urine samples obtained before TURBT
2. Tissue samples obtained at TURBT
3. BCG response = no recurrence at 2 years
4. IL-10 & CXCL10 levels measured by ELISA and RT-qPCR
5. Number of macrophages and M2 polarized measured by immunohistochemistry, using CD163 and CD68

RESULTS *20 patients analyzed*





@DrFelixGuerrero

RESULTS (cont.)

** p < 0.01
**** p < 0.0001





CONCLUSIONS

1. The presence of **M2 polarized** macrophages in TURBT tissue **correlates** with the levels of **IL-10 & CXCL10** in **urine**.
2. Both M2 cells in tissue and IL-10/CXCL10 in urine appear to be **predictive for BCG response.**
3. However, **validation in a larger cohort** is needed to confirm our data.